- Home
- AIRS vs ENLV Comparison
AIRS vs ENLV Comparison
Compare AIRS & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIRS | ENLV |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.8M | 196.2M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AIRS | ENLV |
|---|---|---|
| Price | $3.32 | $0.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 1.3M | 525.5K |
| Earning Date | 05-12-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $151,818,000.00 | N/A |
| Revenue This Year | $5.19 | N/A |
| Revenue Next Year | $5.32 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.51 | $0.66 |
| 52 Week High | $12.00 | $2.10 |
Technical Indicators
Market Signals| Indicator | AIRS | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 65.81 | 40.71 |
| Support Level | $2.43 | $0.77 |
| Resistance Level | $3.36 | $1.23 |
| Average True Range (ATR) | 0.27 | 0.06 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 75.53 | 27.19 |
Price Performance
Historical ComparisonAbout AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.